Tesamorelin is a research peptide built from full-length growth hormone-releasing hormone (GHRH).

Tesamorelin is a research peptide built from full-length growth hormone-releasing hormone (GHRH). Its N-terminal modification is a small chemical group attached at the chain's first end. It was designed to resist one enzyme-driven breakdown route while keeping the GHRH receptor as its target.

GHRH is a hormone signal from the brain that acts on the pituitary gland. It binds the GHRH receptor on somatotrophs, the pituitary cells that release growth hormone (GH).
The GHRH receptor is a cell-surface protein linked to G proteins. When GHRH activates it, the cell raises cyclic AMP, an inside-cell signal that helps prompt GH release.
GH release normally occurs in pulses, meaning short rises separated by lower periods. GHRH helps shape this pulsatile pattern, along with other signals that act on the pituitary.
This pathway explains tesamorelin's class and target. It is a GHRH receptor agonist, meaning it binds to and activates the receptor.
After pituitary release, GH acts on tissues beyond the pituitary. It can promote lipolysis in adipose depots, including visceral depots, mobilizing stored triglycerides; GH also signals the liver and other tissues to produce IGF-I. This provides a plausible downstream route by which pituitary stimulation may alter visceral adipose tissue over time. It is an indirect, systemic effect, not tesamorelin binding to visceral tissue, and receptor activation alone does not establish the size of that change.
Tesamorelin retains the 44 amino acids of GHRH(1-44), the full-length form of the hormone. Its design adds a trans-3-hexenoyl group to the peptide's N-terminus, or first end.

The terms trans-3-hexenoic acid and trans-3-hexenoyl describe related forms of this change. The acid name refers to the separate chemical; the "enoyl" name refers to the part attached to the peptide.
Native GHRH begins with the amino acids tyrosine and alanine. Dipeptidyl peptidase-4 (DPP-4) is an enzyme that can clip off two amino acids from a peptide's front end. The tesamorelin group is intended to make that cleavage harder.
This is a stability design, not a change to the named receptor target. But an added chemical group can still affect receptor binding or signaling, so those properties need their own tests.
The design rationale is distinct from proof of broad stability. A DPP-4 test can measure how much intact peptide remains under that enzyme's conditions. It cannot, by itself, establish stability in plasma, cell media, storage, or other settings.
Keeping all 44 amino acids preserves the full GHRH sequence while adding protection at its first end. This avoids shortening the chain as a way to change how quickly enzymes can break it down.
A shorter sequence can behave differently at the receptor. Comparing full-length tesamorelin with a fragment therefore tests more than stability. It also changes the peptide being presented to the receptor.
At the receptor level, retaining the complete native chain preserves the full sequence and spacing of GHRH residues that the receptor encounters; a fragment would remove part of that ligand and could alter recognition or activation as well as degradation. This is a design rationale, not proof that tesamorelin has the same binding strength or signaling potency as native GHRH. Those questions require direct binding and cyclic AMP assays, interpreted at matched concentrations of intact peptide.
Tesamorelin was designed as a synthetic version of GHRH with a chemical addition at its first end. A common way to make such peptides is solid-phase peptide synthesis, a method that builds a chain one amino acid at a time on a solid support.
Tesamorelin activates the pituitary GHRH receptor and prompts cells to release GH. Direct GH exposure supplies the hormone itself, so it does not test the same signal at the pituitary receptor.

The linked measured mean overnight GH concentration; after 14 days of tesamorelin treatment, it increased by 0.5 ± 0.1 μg/liter.
A human study measured mean overnight GH after tesamorelin.
That human result shows a measured change in GH. It does not prove that the N-terminal group caused resistance to DPP-4 or that the peptide stays intact in every test setting.
Tesamorelin, sermorelin, and CJC-1295 are linked to GHRH, but they do not share the same structure. Ipamorelin differs more sharply: it acts at the ghrelin receptor, not the GHRH receptor.
| Peptide | Structure | Main receptor action | Key study distinction |
|---|---|---|---|
| Tesamorelin | Full-length GHRH(1-44), with an N-terminal group | Activates the GHRH receptor | Human hormone studies; stability needs separate tests |
| Sermorelin | Shorter GHRH fragment | Activates the GHRH receptor | Fragment studies do not test the full-length design |
| CJC-1295 | GHRH-related 30-amino-acid peptide | Acts through the GHRH receptor | Keep versions with and without DAC distinct |
| Ipamorelin | Five-amino-acid peptide | Activates the ghrelin receptor | Tests a different receptor class |
GHRH analogues and ghrelin-receptor secretagogues are not interchangeable controls. A secretagogue is a signal that prompts hormone release, but the receptor it acts on shapes the result.
For example, a difference between tesamorelin and ipamorelin could come from their receptor targets, their structures, or both. A sound comparison measures receptor activity and peptide breakdown separately.
Cell studies can measure receptor binding, cyclic AMP signals, and enzyme-driven breakdown. They help separate a weak receptor response from a sample that has already lost intact peptide.

Animal studies can track hormone patterns and intact peptide in a living system. Human hormone studies can measure changes in hormone levels, but those results alone do not identify the exact enzyme or bond involved.
To separate breakdown from receptor signaling, researchers can measure intact peptide at set time points and test receptor activity in parallel. A control without the enzyme can show whether the enzyme changed the amount of intact material.
Peptide half-life means the time it takes for the measured amount of intact peptide to fall by half under stated conditions. It is not a fixed feature across all samples, since enzymes, temperature, solution, and test method can change the result.
High-performance liquid chromatography (HPLC) separates peptide-related compounds as they pass through a column. HPLC purity usually reports the share of detected signal assigned to the main peak. It does not, by itself, show the total peptide content in a sample.
Mass spectrometry measures the mass of detected molecules and can support identity checks. Tandem mass spectrometry breaks molecules into smaller pieces, which can help check sequence and locate a chemical change.
Purity and content answer different questions. Purity concerns the mix of detected material; content concerns how much of the named peptide is present in the sample.
A certificate of analysis should identify the tested batch, methods, results, and test lab. The linked pages describe laboratory testing and certification information. Those records help assess what was tested, while a stability claim still needs tests under stated conditions.
Stability testing should name the sample type, temperature, time points, and method used to measure intact peptide. A storage or shipping record can add context, but it cannot replace a stability assay.
Tesamorelin's design keeps full-length GHRH(1-44) and adds a trans-3-hexenoyl group at the N-terminus. The change aims to hinder one enzyme-driven cut while preserving the GHRH receptor target.
Tests must separate peptide breakdown from receptor activity. A result for one enzyme, sample type, or condition does not establish stability in all settings.